Treating Gastric Cancer Using TTFields Combined with XELOX, FOLFOX or the Individual Constituents Thereof
Methods of treating gastric cancer and reducing the viability of gastric cancer cells by administering folinic acid, fluorouracil, and oxaliplatin to a subject, and applying an alternating electric field to a target region of the subject are provided. In some instances, chemotherapy such as XELOX, FOLFOX and individual components thereof are administered to a subject followed by applying an alternating electric field to the subject.
1 . A method of treating gastric cancer in a subject, the method comprising:
administering oxaliplatin and capecitabine to the subject; and
applying an alternating electric field to a target region of the subject, the alternating electric field having a frequency between 100 and 400 kHz.
2 . The method of claim 1 , wherein at least a portion of the applying is performed after the administering and before the oxaliplatin and capecitabine are eliminated from the subject's body.
3 . The method of claim 1 , wherein the applying has a duration of at least 72 hours.
4 . The method of claim 1 , wherein the frequency of the alternating electric field is between 120 and 180 KHz.
5 . The method of claim 1 , wherein the frequency of the alternating electric field is between 145 and 155 kHz.
6 . The method of claim 1 , wherein the oxaliplatin and capecitabine are administered at therapeutically effective doses, and wherein the alternating electric field has a field strength of at least 1 V/cm in at least a portion of the target region.
7 . The method of claim 6 , wherein the applying has a duration of at least 72 hours and wherein the frequency of the alternating electric field is between 120 and 180 KHz.
8 . The method of claim 6 , wherein the applying has a duration of at least 72 hours and wherein the frequency of the alternating electric field is between 145 and 155 kHz.
9 . A method of reducing viability of gastric cancer cells, the method comprising:
administering oxaliplatin and capecitabine to the cancer cells; and
applying an alternating electric field to the cancer cells, the alternating electric field having a frequency between 100 and 400 kHz.
10 . The method of claim 9 , wherein at least a portion of the applying is performed simultaneously with at least a portion of the administering.
11 . The method of claim 9 , wherein the applying has a duration of at least 72 hours.
12 . The method of claim 9 , wherein the frequency of the alternating electric field is between 120 and 180 kHz.
13 . The method of claim 9 , wherein the frequency of the alternating electric field is between 145 and 155 kHz.
14 . The method of claim 9 , wherein each of the oxaliplatin and capecitabine is delivered to the cancer cells at a therapeutically effective concentration, and wherein the alternating electric field has a field strength of at least 1 V/cm in at least some of the cancer cells.
15 . The method of claim 14 , wherein the applying has a duration of at least 72 hours and wherein the frequency of the alternating electric field is between 120 and 180 kHz.
16 . The method of claim 14 , wherein the applying has a duration of at least 72 hours and wherein the frequency of the alternating electric field is between 145 and 155 kHz.